

Reference number(s)
2860-A

## SPECIALTY GUIDELINE MANAGEMENT

### INBRIJA (levodopa inhalation powder)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication

Inbrija is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa.

All other indications are considered experimental/investigational and not medically necessary.

##### II. EXCLUSIONS

Coverage will not be provided for members with any of the following exclusions:

- A. Asthma
- B. Chronic obstructive pulmonary disease (COPD)
- C. Other chronic underlying lung disease
- D. Members who are receiving concomitant treatment with nonselective monoamine oxidase (MAO) inhibitors (e.g. phenelzine, tranylcypromine)

##### III. CRITERIA FOR INITIAL APPROVAL

##### **Parkinson's disease**

Authorization of 6 months may be granted for intermittent treatment of "off" episodes in members with Parkinson's disease when all of the following criteria are met:

- A. The member experiences at least 2 hours per day of off time
- B. The member is currently being treated with oral carbidopa/levodopa
- C. Attempts to manage off episodes by adjusting the dosing or formulation of carbidopa/levodopa were ineffective
- D. Treatment with carbidopa/levodopa plus one of the following therapies was ineffective at managing off episodes:
  1. Dopamine agonist (e.g., pramipexole, ropinirole)
  2. Monoamine oxidase B (MAO-B) inhibitor (e.g., selegiline, rasagiline)
  3. Catechol-O-methyl transferase (COMT) inhibitor (e.g., entacapone, tolcapone)

##### IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for intermittent treatment of "off" episodes in members with Parkinson's disease when all of the following criteria are met:

- A. The member is currently being treated with oral carbidopa/levodopa

Reference number(s)
2860-A

- B. The member is experiencing improvement on Inbrija therapy (e.g., reduction in daily off time, improvement in motor function post-administration)

## V. REFERENCES

1. Inbrija [package insert]. Ardsley, NY: Acorda Therapeutics, Inc.; September 2019.
2. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review. *Neurology* Jan 2002, 58 (1) 11-17.
3. National Institute for Clinical Excellence: Parkinson's disease in adults. July 2017. <https://www.nice.org.uk/guidance/ng71/resources/parkinsons-disease-in-adults-pdf-1837629189061>. Accessed August 15, 2019.
4. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. *Mov Disord*. 2018; 33(8):1248-1266.